Skip Navigation LinksHome > December 1, 2013 - Volume 64 - Issue 4 > Infant Growth Outcomes After Maternal Tenofovir Disoproxil F...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a7adb2
Clinical Science

Infant Growth Outcomes After Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy

Ransom, Carla E. MD*; Huo, Yanling MS; Patel, Kunjal DSc, MPH†,‡; Scott, Gwendolyn B. MD§; Watts, Heather D. MD; Williams, Paige PhD; Siberry, George K. MD, MPH; Livingston, Elizabeth G. MD; for the P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Collapse Box

Abstract

Objective: To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth.

Methods: The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002–2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, χ2 test, and multivariable linear and logistic regression models, including demographic and maternal characteristics.

Results: Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age- and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth.

Conclusions: By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.

© 2013 by Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.